| Product Type | Impurity Standards |
| CAT. No. | MRL-O09003 |
| CAS. No. | NA |
| Mol. Formula | C28H32N8O3 |
| Mol. Weight | 528.62 |
| Synonyms | NA |
| Chemical Name | N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)(nitroso)amino)phenyl)acrylamide |
| HSN Code | 38229010 |
| Country of Origin | India |
| Stock Status | Please Enquire |
Nitrosamines can be formed through various chemical processes, including the reaction between nitrites and secondary amines in certain conditions. It is a N-Nitroso of secondary amine present in Osimertinib. Nitrosamines are part of a broader class of compounds known as N-nitroso compounds. Osimertinib is a targeted therapy medication primarily used in the treatment of advanced non-small cell lung cancer (NSCLC) that has specific mutations in the epidermal growth factor receptor (EGFR) gene. It belongs to the class of tyrosine kinase inhibitors and is particularly effective against NSCLC with EGFR mutations, such as the T790M mutation. Osimertinib works by blocking the activity of the mutated EGFR protein, which is often associated with the growth and survival of cancer cells. By inhibiting this aberrant signaling, osimertinib helps slow down or shrink the tumor, providing a treatment option for patients with EGFR-mutated NSCLC, especially those who have developed resistance to other EGFR inhibitors. Its targeted approach makes osimertinib a significant advancement in the personalized treatment of lung cancer. Buy high quality N-Nitroso Osimertinib from Molsyns Research. Molsyns Research is one of the leading manufacturer and exporter of N-Nitroso Osimertinib